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Brachial plexus injury, causalgia, complex neonatal nurse who developed left hand burning pain, regional pain syndrome, labor, pregnancy, reflex symswelling, coldness, and weakness following a mild brapathetic dystrophy, spinal cord stimulation. chial plexus injury in a motor vehicle accident. The patient responded well to a combination of Neurontin, Trazadone, Ultram, and Vicodin. A year later, the patient
Complex regional pain syndromes (CRPS) clinical
married and wanted to become pregnant but was course, physiopathology, and choice of treatment afraid of possible teratogenic effects of the medicamodalities remain subjects of debate. However, it tions. Therefore, she requested an interventional modality for control of her symptoms. We recommended occurs more frequently in middle-aged adults with spinal cord stimulation (SCS) based on our excellent exa female to male ratio of 2 or 3 to 1 and even perience with this modality in the management of com-4.5 to 1 (1,2). According to the Bureau of Labor plex regional pain syndromes (CRPS). However, we did Statistics, today more than 57% of women are part inform the patient that no data had been published of the workforce (3), and the tendency is for women regarding the safety of this modality in pregnancy and to wait until later in their physiologic reproductive Her responses were compared thectomy). We describe the case of a female discontinuing a medication regime which successwith those of a normative sample of chronic pain patients. Her results suggested that her depression fully controlled her CRPS to have a spinal cord stimulator implanted so that she could become pregnant score was in the average range for chronic pain patients and slightly higher than the cutoff which without the risk of possible teratogenic effects from medication.
is suggestive of a possibility of a mood disorder. Otherwise, marital satisfaction and family support appeared to be better than average for this population. No animal or human studies regarding possible CASE REPORT teratogenic effects or fetal/maternal risk using SCS at the time of conception, pregnancy, and labor On March 25, 1996, a 31 year-old, right-handed female nurse was injured in a motor vehicle accident were available, and this was explained to the patient who signed an informed consent. In July, 1997 she in which she was rear-ended by a car going 60 mph. She suffered a whiplash neck injury, developed an underwent a successful three-day trial of cervical SCS with a Medtronic Resume TL thin line lead (a immediate onset of weakness and sensation loss in her left hand, and five days later, noticed her left Quad lead could not be advanced percutaneously) on the left dorsal epidural quadrant with the 0 elechand was swollen and bluish. She was admitted for intensive management which included a stellate trode at the C2-3 level and a Medtronic Itrel-III pulse generator (Minneapolis, MN) was implanted in the ganglion block resulting in a Horner's syndrome with pain relief lasting for 10 days. An electromicroupper gluteal region instead of the abdomen because of the patient's concern of discomfort during graph confirmed a mild brachial plexus injury. Cervical spine X-rays were within normal limits. MRI of pregnancy and risk of damage if a caesarean section was necessary. She had excellent pain control (close the brachial plexus was unremarkable; but the cervical spine study revealed a Chiari I malformation, to 100%) and dramatic decrease of her allodynia/ hyperpathia using less than 1 volt amplitude, 180 although that was considered incidental. She regained strength and sensation but developed burnsec pulse width, and a rate of 55 pps. She noticed that the pain recurred in 45-60 min after turning ing pain in her left hand and an inability to tolerate touch, movement, temperature fluctuation, or air the stimulator off, and therefore used it 24 h a day. After having been successfully tapered off medicacurrent, and she subsequently required the use of a sling and a cloth to keep the hand protected. She tions, she became pregnant and delivered a healthy, five-pound baby female 5 weeks early on August 8, noticed bluish discoloration and the hand became sweaty and cold. She was evaluated at a multidiscipli-1998. At no time during the labor and delivery was the SCS turned off. Both mother and baby were nary clinic and with a pharmacological regime of Neurontin 600 mg twice a day, Trazadone 100 mg discharged from the hospital in two days. (Fig. 1 ) at bed time, Tramadol 50 mg four times a day, Vicodin and Motrin, she obtained satisfactory pain control. She later married and wanted to become DISCUSSION pregnant, but was afraid of possible teratogenic effects of these medications. The pain clinic referred Pregnancy has been reported as a predisposing factor for CRPS, but there is no data about whether her for evaluation for an interventional pain control procedure which would allow discontinuation of pregnancy would aggravate a pre-existing syndrome (5). Therefore, there was not a formal contramedication.
On evaluation, her left hand had bluish discolorindication for our patient with CRPS to get pregnant.
measured by quantitative noninvasive assessment of autonomic function (10). We believe SCS has to be offered as the first choice for interventional augmentative modality before of intra-axial continuous infusion.
A literature search on the use of SCS in humans at the time of either conception, pregnancy, or labor/ delivery retrieved only one study, effects of transcutaneous electrical nerve stimulation (TENS) on hormonal parameters of placental function in cases of placental insufficiency (11). A significant elevation of HPL and Estriol serum levels were found; a correlation between the onset of therapy at a certain week of gestation and its effect could not be proved.
In any case, even if these results could be extrapolated to SCS, they are not harmful for gestation. However, the possible consequences to the developing embryo need to be considered.
We would also like to speculate about what other mechanisms may be influenced by SCS during pregnancy and labor. It has been demonstrated that during pregnancy and labor in rats, guinea pigs, and humans, there is an opioid-mediated elevation in the threshold for responsiveness to aversive stimuli which reaches a maximum at term. In rats this is nancy. For example, threshold is dependent on the integrity of the hypogastric nerve (12) . Although it has been proposed that the SCS analgesic effects may result from release of endorphins (13) , it has Medications are classified in the pharmacopeia (6) according to the evidence existing in the literabeen shown that they are not affected by Naloxone (14) . Whether SCS may reinforce the physiologic ture regarding possible teratogenic effects in the following risk categories: ''A'' (controlled studies in analgesic mechanisms occurring during pregnancy and labor therefore remains unknown. women showing no risk), ''B'' (animal studies do not show risk but no adequate human studies have
The mechanisms determining the onset of labor are not well understood, but the control of the uterbeen done), ''C'' (animal studies show some fetal risk but or no animal/controlled studies have been ine contractions is predominantly hormonal and not neurogenic. Autonomic neural input to the uterus done), and ''D'' (evidence of human fetal risk). Our patient was receiving Trazadone (category C; exmay actually decrease myometrial contractions (15) and there is loss of uterine body adrenergic fibers cretion into breast milk unknown), Vicodin (category C: 7.2% teratogenic effects; is not excreted (16) and involution of peptidergic neurons late in pregnancy (17) . Further proof of the lack of relein breast milk), Motrin (category B; is not excreted in breast milk), Tramadol (category C; excretion into vance of neurogenic control is the fact that paraplegic women may deliver (18) . breast milk unknown), and Neurontin (not available). Therefore, our patient's wish to discontinue A literature search on animal laboratory studies regarding SCS and pregnancy revealed milk ejection her medications before she became pregnant seemed reasonable.
was obtained by electrical stimulation of the anterolateral spinal cord in lactating rats; the responses Spinal cord stimulation is effective in the treatment of CRPS (7-9). Improvements are objectively were eliminated after destruction of the pituitary stalk and were not associated with blood pressure ACKNOWLEDGMENT changes. It was concluded that they resulted from
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It has been postulated that electromagnetic field forces (EMF) induced by electrical equipment may REFERENCES cause cancer in humans, but it is unlikely they will cause birth defects or miscarriages (20 . SCS was proven to be safe in our case study of a female wanting to become pregnant. This would 9. Kumar K, Nath RK, Toth C. Spinal cord stimulation is effective in the management of reflex be especially relevant because CRPS is seen more frequently in middle-aged adults with a significant sympathetic dystrophy. Neurosurgery 1997;40: 503-509. female preponderance. Taking into account the modern tendency of late maternity, the dilemma of 10. Segal R, Guliani M, Stacey BR, Ott M-B. Quantitative assessment of results of spinal cord stimulahow to manage CRPS in a female in the reproductive years may present more frequently. We are hopeful tion (SCS) in RSD by autonomic function tests. In: International Neuromodulation Society 4 th Interthis publication will elicit the interest of pain specialists elsewhere to report other cases of conception, national Congress Abstract Book. Lucerne, Switzerland. 1998; p. 158. pregnancy, and delivery in patients using SCS, in order to confirm that safety of this modality under 11. Kubista E. The influence of transcutaneous nerve stimulation (TNS) on hormonal parameters these circumstances.
